Onco-Innovations Collaborates with AstraZeneca on AI in Oncology

Onco-Innovations Limited, through its subsidiary Inka Health, has initiated a research collaboration with AstraZeneca. This partnership is part of the PROmAI program aiming to predict oncology outcomes using multimodal artificial intelligence. The focus is on developing AI models to enhance clinical outcome predictions in oncology.

The collaboration uses various data sources, such as molecular and clinical data, to understand patient heterogeneity and treatment responses better. This aligns with a shared goal to improve decision-support tools for oncology research and development.

The partnership marks a significant step for Onco in using AI for drug development challenges. It provides insights that could improve predictive modeling, meeting regulatory and payer expectations. AstraZeneca's expertise in oncology is seen as vital to developing reliable AI methods.

Thomas O'Shaughnessy, CEO, remarked on the potential of this collaboration to uncover insights that traditional methods might miss, potentially reducing uncertainty in oncology development.